Shoji Nagao

Prof. Shoji Nagao

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Gynecologic Oncology
Verified
Journal Article
Closed access
SNShoji Nagao
Shoji Nagao
Shin NishioShin Nishio
Shin Nishio
HMHirofumi Michimae
Hirofumi Michimae
HTHiroshi Tanabe
Hiroshi Tanabe
SOSatoshi Okada
Satoshi Okada
JKJunzo Kigawa
Junzo Kigawa

29 June 2016 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
KNKazuto Nakamura
Kazuto Nakamura
YKYoshikazu Kitahara
Yoshikazu Kitahara
TSToyomi Satoh
Toyomi Satoh
YTYuji Takei
Yuji Takei
MTMasashi Takano
Masashi Takano
MSMitsuaki Suzuki
Mitsuaki Suzuki
There are no definitive criteria for identifying which patients with The International Federation of Gynecology and Obstetrics (FIGO) stage IB cervical cancer will benefit from adjuvant therapy after radical hysterectomy. The aims of this study were to clarify the efficacy of adjuvant therapy and assess complications after radical hysterectomy in patients with FIGO stage IB1 cervical cancer with intermediate risk factors. Between January 2005 and December 2009, the medical records of 75 stage IB1 patients’ intermediate risk factors (i.e., tumor size 2–4 cm, lymphovascular involvement, and/or deep stromal invasion >1/2) who underwent radical hysterectomy at six institutions were collected, and these patients were enrolled in this nonrandomized retrospective study. We simplified the criteria of intermediate risk factors as much as possible, as the criteria adopted in some clinical studies are complicated in practice. The patients were grouped according to the receipt of adjuvant therapy as follows: 46 patients, no further treatment; 19 patients, external beam radiation treatment, including 9 patients who received brachytherapy; 5 patients, concurrent chemoradiotherapy (CCRT); and 5 patients, chemotherapy (CT). The clinical outcomes and complications in each group were analyzed. After an average follow-up of 82.6 months (range, 24–135 months), only one patient with all three risk factors who received radiotherapy (RT) experienced recurrence. Excluding this patient, the remaining patients who received RT, CCRT, or CT had two or three risk factors. Lymphedema was significantly more common among patients who received RT or CCRT, whereas the incidence of ileus and ureteral obstruction was not different among the treatment groups. However, an unsutured peritoneum increased the risk of ileus. The findings of this study suggest that RT and CCRT after radical hysterectomy are not beneficial in patients with intermediate risk factors. In particular, RT and CCRT appeared to increase the incidence of lymphedema. A prospective randomized study is needed to verify the findings of this study.

1 December 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
KYKasumi Yamamoto
Kasumi Yamamoto
SNShoji Nagao
Shoji Nagao
KSKazuhiro Suzuki
Kazuhiro Suzuki
AKAi Kogiku
Ai Kogiku
TSTokihiro Senda
Tokihiro Senda
SYSatoshi Yamaguchi
Satoshi Yamaguchi

1 September 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
KSKazuhiro Suzuki
Kazuhiro Suzuki
SNShoji Nagao
Shoji Nagao
TSTakashi Shibutani
Takashi Shibutani
KYKasumi Yamamoto
Kasumi Yamamoto
TJTomoatsu Jimi
Tomoatsu Jimi
SYSatoshi Yamaguchi
Satoshi Yamaguchi

17 January 2023 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYusuke Kajimoto
Yusuke Kajimoto
KHKazunori Honda
Kazunori Honda
SSSHIRO Suzuki
SHIRO Suzuki
MMMasahiko Mori
Masahiko Mori
HTHirofumi Tsubouchi
Hirofumi Tsubouchi
AIAtaru Igarashi
Ataru Igarashi

20 June 2015 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SNShoji Nagao
Shoji Nagao
Shin NishioShin Nishio
Shin Nishio
SOSatoshi Okada
Satoshi Okada
TOTakeo Otsuki
Takeo Otsuki
KFKiyoshi Fujiwara
Kiyoshi Fujiwara
JKJunzo Kigawa
Junzo Kigawa